Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    18005144 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day
2 Completed Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day

Indicates status has not been verified in more than two years